562 related articles for article (PubMed ID: 25068703)
1. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
[TBL] [Abstract][Full Text] [Related]
2. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
[TBL] [Abstract][Full Text] [Related]
3. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming.
Zupančič E; Curato C; Paisana M; Rodrigues C; Porat Z; Viana AS; Afonso CAM; Pinto J; Gaspar R; Moreira JN; Satchi-Fainaro R; Jung S; Florindo HF
J Control Release; 2017 Jul; 258():182-195. PubMed ID: 28511928
[TBL] [Abstract][Full Text] [Related]
4. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen.
Saluja SS; Hanlon DJ; Sharp FA; Hong E; Khalil D; Robinson E; Tigelaar R; Fahmy TM; Edelson RL
Int J Nanomedicine; 2014; 9():5231-46. PubMed ID: 25419128
[TBL] [Abstract][Full Text] [Related]
5. Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine.
Jahan ST; Sadat SM; Haddadi A
Int J Nanomedicine; 2018; 13():367-386. PubMed ID: 29391795
[TBL] [Abstract][Full Text] [Related]
6. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation.
Silva AL; Rosalia RA; Varypataki E; Sibuea S; Ossendorp F; Jiskoot W
Vaccine; 2015 Feb; 33(7):847-54. PubMed ID: 25576216
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4
Tang XD; Lü KL; Yu J; Du HJ; Fan CQ; Chen L
Cancer Immunol Immunother; 2022 Dec; 71(12):2969-2983. PubMed ID: 35546204
[TBL] [Abstract][Full Text] [Related]
9. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells.
Heo MB; Cho MY; Lim YT
Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635
[TBL] [Abstract][Full Text] [Related]
10. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response.
Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G
ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266
[TBL] [Abstract][Full Text] [Related]
11. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
12. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
[TBL] [Abstract][Full Text] [Related]
13. Activation of Antigen-Specific CD8(+) T Cells by Poly-DL-Lactide/Glycolide (PLGA) Nanoparticle-Primed Gr-1(high) Cells.
Luo WH; Yang YW
Pharm Res; 2016 Apr; 33(4):942-55. PubMed ID: 26715415
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM
Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with trifunctional nanoparticles that address CD8
Shen L; Krauthäuser S; Fischer K; Hobernik D; Abassi Y; Dzionek A; Nikolaev A; Voltz N; Diken M; Krummen M; Montermann E; Tubbe I; Lorenz S; Strand D; Schild H; Grabbe S; Bros M
Nanomedicine (Lond); 2016 Oct; 11(20):2647-2662. PubMed ID: 27628310
[TBL] [Abstract][Full Text] [Related]
16. Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.
Rosalia RA; Silva AL; Camps M; Allam A; Jiskoot W; van der Burg SH; Ossendorp F; Oostendorp J
Cancer Immunol Immunother; 2013 Jul; 62(7):1161-73. PubMed ID: 23613147
[TBL] [Abstract][Full Text] [Related]
17. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles.
Hamdy S; Haddadi A; Shayeganpour A; Samuel J; Lavasanifar A
Pharm Res; 2011 Sep; 28(9):2288-301. PubMed ID: 21560020
[TBL] [Abstract][Full Text] [Related]
18. Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response.
Song C; Noh YW; Lim YT
Int J Nanomedicine; 2016; 11():3753-64. PubMed ID: 27540289
[TBL] [Abstract][Full Text] [Related]
19. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.
Cruz LJ; Tacken PJ; Pots JM; Torensma R; Buschow SI; Figdor CG
Biomaterials; 2012 Jun; 33(16):4229-39. PubMed ID: 22410170
[TBL] [Abstract][Full Text] [Related]
20. CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses.
Castro FV; Tutt AL; White AL; Teeling JL; James S; French RR; Glennie MJ
Eur J Immunol; 2008 Aug; 38(8):2263-73. PubMed ID: 18651710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
